is fluvoxamine fda approved for major depression? no, its u.s. labels list only ocd
“Unlike several other SSRIs, it isn't FDA approved for major depression.”
a host said on Psychopharmacology and Psychiatry Updates, 2026-10-03, at 01:36. hear it in context →
the episode: SSRI Dosing for OCD: Beyond FDA Guidelines (at 01:36). we link the show's own page; we do not re-host audio.
first, the part that holds
the host is right. every current FDA label we read for fluvoxamine, both the immediate-release tablets and the extended-release capsules, lists obsessive compulsive disorder as the only indication. major depressive disorder isn't there.
what we found when we went and looked
we read three FDA-approved fluvoxamine labels. the 2012 tablet label on accessdata.fda.gov (initial U.S. approval 1994) has one indication, section 1.1 obsessive-compulsive disorder. a generic tablet label on DailyMed revised 2/2024 and a generic extended-release capsule label revised 10/2023 also list only OCD. for comparison, the fluoxetine label lists "acute and maintenance treatment of major depressive disorder (MDD)" as its first indication. one detail cuts both ways: the fluvoxamine tablet label pools side-effect data from "controlled trials with adult OCD and depression patients", so the drug was studied in depression, but the FDA approval covers OCD only.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| fluvoxamine is not FDA approved for major depressive disorder | confirmed | the tablet label (accessdata.fda.gov, 2012) has one indication, section 1.1 obsessive-compulsive disorder. a generic tablet label (DailyMed, rev. 2/2024) and a generic extended-release capsule label (DailyMed, rev. 10/2023) also list only OCD. none of them lists major depressive disorder. limitation: we read labels, not the full approval history in Drugs@FDA for every application [1][2][3] |
| several other SSRIs are FDA approved for major depression | confirmed | the fluoxetine label (2017) lists acute and maintenance treatment of major depressive disorder as its first indication. we read only this one comparator label, so 'several' rests on one fetched example plus the general picture of the class [4] |
| fluvoxamine was studied in depression even though it is not approved for it | confirmed | the adverse reactions summary on the tablet label describes the most common reactions 'in controlled trials with adult OCD and depression patients'. the label doesn't report depression efficacy results, and the indication stayed limited to OCD [1] |
| fluvoxamine's pediatric approval is limited to OCD | confirmed | the boxed warning says the tablets 'are not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD)'. the capsule label says safety and effectiveness outside pediatric OCD have not been established [1][3] |
both directions
for the speaker: all three fluvoxamine labels we read, covering both tablets and extended-release capsules and spanning 2012 to 2024, list OCD as the only indication. the fluoxetine label lists major depressive disorder first among its indications, which supports the "unlike several other SSRIs" framing.
against: there's nothing in the FDA record against the claim itself. two things are easy to misread, though. first, the tablet label's boxed warning talks about suicidality in "short-term studies of major depressive disorder (MDD)". that is class-wide antidepressant language, not an approval for depression. second, the label says fluvoxamine was given to depression patients in controlled trials. so "not approved" is a regulatory status. it doesn't mean the drug was never tested in depression, and the labels don't say it failed.
what this cannot say
a label tells you what the FDA approved. it doesn't tell you whether a drug works for an unlisted condition, and doctors can legally prescribe approved drugs off-label. this check is about the U.S. only. we didn't read regulatory records outside the U.S., where fluvoxamine's approved uses may be different, so the claim shouldn't be taken as true worldwide. we read three fluvoxamine labels and one comparator label, not the full approval history in Drugs@FDA or every other SSRI's label.
sources, each one fetched and read
- U.S. Food and Drug Administration. Fluvoxamine maleate tablets prescribing information, NDA 021519 (s003), 2012. accessdata.fda.gov What we read there: "Fluvoxamine Maleate Tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD), as defined in DSM-III-R or DSM-IV." initial U.S. approval 1994. the boxed warning says the tablets "are not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD)." the adverse reactions summary cites "controlled trials with adult OCD and depression patients." Fetched 2026-10-14 (HTTP 200). https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
- National Library of Medicine, DailyMed. Fluvoxamine maleate tablet label (generic labeler), revised 2/2024 What we read there: "Fluvoxamine maleate tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD)." no other indication is listed. Fetched 2026-10-14 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6eeb14df-6fcf-a737-5359-5744eb4accea
- National Library of Medicine, DailyMed. Fluvoxamine maleate extended-release capsules prescribing information, revised 10/2023 (initial U.S. approval 2008) What we read there: "Fluvoxamine maleate extended-release capsules are selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of obsessive compulsive disorder (OCD)." pediatric use: safety and effectiveness outside pediatric OCD "have not been established." Fetched 2026-10-14 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9924422b-7c90-42bf-a680-ffd92063d5f0&type=display
- U.S. Food and Drug Administration. Fluoxetine capsules and delayed-release capsules prescribing information, NDA 018936 (s108), 2017. accessdata.fda.gov What we read there: indications include "acute and maintenance treatment of Major Depressive Disorder (MDD)", plus OCD, bulimia nervosa and panic disorder. initial U.S. approval 1987. Fetched 2026-10-14 (HTTP 200). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam